Ladenburg Thalmann & Co. Sticks to Their Buy Rating for Marinus (MRNS)

By Ryan Adsit

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. reiterated a Buy rating on Marinus (MRNSResearch Report), with a price target of $5.00. The company’s shares closed last Monday at $1.64, close to its 52-week low of $0.77.

According to TipRanks.com, Higgins is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -11.2% and a 31.8% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Armata Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Achieve Life Sciences Inc.

Currently, the analyst consensus on Marinus is a Strong Buy with an average price target of $4.00.

See today’s analyst top recommended stocks >>

Based on Marinus’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $12.42 million. In comparison, last year the company had a GAAP net loss of $9.5 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.